OmniAb(NASDAQ) OABIW

Market CapN/A

Since IPO (2021)-45%

5 YearN/A

1 Year+46%

1 Month+278%

$0.30

+30.44%

+0.07Today

OmniAb last closing stock price
Metric	Price	Date
Last close	USD 0.30	2026-08-26

OmniAb stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+57.89%	USD 0.19	2026-08-19
1 month	+278.31%	USD 0.08	2026-07-23
3 month	+200%	USD 0.10	2026-05-28
Year to date	+150.21%	USD 0.12	2025-12-31
1 year	+46.06%	USD 0.21	2025-08-26
3 year	-75.31%	USD 1.22	2023-08-25
Since inception	-45.45%	USD 0.55	2021-09-30

OmniAb Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$38.43M

Net Income (TTM)

-$44.26M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.40 (Low)

Dividend

$0.00

Beta (Volatility)

0.40 (Low)

Price

$0.30

Volume

15,487

Open

$0.23

Price

$0.30

Volume

15,487

Open

$0.23

Previous Close

$0.30

Daily Range

$0.20 - $0.33

52-Week Range

$0.04 - $0.40

Estimated Earnings Date

Nov 17, 2026

Dividend

$0.00

Beta (Volatility)

0.40 (Low)

Price

$0.30

Volume

15,487

Open

$0.23

Previous Close

$0.30

Daily Range

$0.20 - $0.33

52-Week Range

$0.04 - $0.40

Estimated Earnings Date

Nov 17, 2026

OABIW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About OmniAb

OmniAb, Inc. is a biotechnology firm based in Emeryville, California, specializing in innovative technologies for therapeutic antibody discovery. Established in 2012, the company offers a unique OmniAb platform that enables partners to develop next-generation therapeutic agents through advanced screening techniques and proprietary transgenic animals.

Products and Services

OmniAb platform for therapeutic antibody discovery
Proprietary transgenic animals: OmniRat, OmniChicken, OmniMouse
Specialized models: OmniFlic and OmniClic for bispecific antibodies

Growth Outlook

Recent quarterly revenue of $13.4 million shows strong market demand
TTM gross profit margin of 50.5% indicates efficient operations
Current ratio of 4.8 suggests strong liquidity position for future growth

Financial Highlights

Q2 2026 revenue of $13.4 million, up from $14 million in Q1 2026
Net income for Q2 2026 was -$5.9 million, reflecting ongoing investment in R&D
Cash and short-term investments totaled $51.9 million as of June 30, 2026

OmniAb, Inc. is positioned in the biotechnology sector with a focus on therapeutic antibody development. The company's proprietary platform and transgenic animals provide a competitive edge in the market. Recent financial performance indicates a solid revenue stream, although the company continues to invest heavily in research and development, which is reflected in the net income figures. The strong liquidity position, as evidenced by the current ratio, supports the potential for future growth and innovation. Overall, OmniAb presents an intriguing opportunity for investors interested in the biotechnology field.

AI Generated • Aug 11, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Headquarters

EmeryVille, CA 94608, US

OABIW Financials

Key Financial Metrics (TTM)

Gross Margin

50.53%

Operating Margin

-125.79%

Net Income Margin

-115.18%

Return on Equity

-16.59%

Return on Capital

-24.89%

Return on Assets

-15.25%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

15.49K

Avg. Volume

10.18K

Financials (TTM)

Gross Profit

$19.42M

Operating Income

-$48.34M

EBITDA

-$25.46M

Operating Cash Flow

-$17.67M

Capital Expenditure

-$468.00K

Free Cash Flow

-$18.14M

Cash & ST Invst.

$52.00M

Total Debt

$18.91M

OmniAb Performance Analysis

OmniAb sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-42.5%
Q4	2025-12-31	274.1%
Q1	2026-03-31	71.9%
Q2	2026-06-30	-6.8%

OmniAb sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	6.7%
Q4	2025-12-31	21.4%
Q1	2026-03-31	45.5%
Q2	2026-06-30	16.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$13.42M

+244.2%

Gross Profit

$12.81M

+252.3%

Gross Margin

95.45%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$5.86M

+63.1%

EBITDA

-$6.21M

+57.4%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$52.00M

+24.9%

Total Debt

$18.91M

-13.2%

Accounts Receivable

$10.33M

+281.7%

Inventory

$0.00

N/A

Long Term Debt

$14.94M

-16.7%

Short Term Debt

$3.97M

+3.4%

Return on Assets

-15.25%

N/A

Return on Invested Capital

-17.48%

N/A

Free Cash Flow

$2.57M

+148.4%

Operating Cash Flow

$2.68M

+152.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CHRSCoherus Oncology, Inc.

CHRSCoherus Oncology, Inc.$1.45+5.84%

CGENCompugen Ltd.

CGENCompugen Ltd.$2.84-1.05%

GNLXGenelux Corporation

GNLXGenelux Corporation$2.73+0.37%

VORVor Biopharma Inc.

VORVor Biopharma Inc.$23.67-1.42%

NTHINeonc Technologies Holdings, Inc.

NTHINeonc Technologies Holdings, Inc.$4.56-3.18%

OBIOOrchestra BioMed Holdings, Inc.

OBIOOrchestra BioMed Holdings, Inc.$5.26-1.87%

IVVDInvivyd, Inc.

IVVDInvivyd, Inc.$0.90-3.94%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$209.66-0.02%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$116.60+0.01%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$48.09-0.01%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$18.65+0.00%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$44.46-0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$70.47+0.00%

BMNRBitmine Immersion Technologies

BMNRBitmine Immersion Technologies$24.91+0.00%

Questions About OABIW

What is the current price of OmniAb?

OmniAb is trading at $0.30 per share.

What is the 52-week range for OmniAb?

Over the past 52 weeks, OmniAb has traded between $0.04 and $0.40.

How much debt does OmniAb have?

OmniAb total debt is unavailable.

How much cash does OmniAb have on hand?

OmniAb does not have cash on hand data available.

What is OmniAb’s dividend yield?

OmniAb does not currently have a dividend yield.

OmniAb(NASDAQ) OABIW

OmniAb Financials at a Glance

OABIW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About OmniAb

OABIW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

OmniAb Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About OABIW

What is the current price of OmniAb?

What is the 52-week range for OmniAb?

How much debt does OmniAb have?

How much cash does OmniAb have on hand?

What is OmniAb’s dividend yield?

Premium Investing Services